Shareholders of Intravenous Infusions PLC has approved the rights issue to raise GH¢50 million to recapitalise the operations of the company.
Though the request by the company, was granted by shareholders at the last AGM in August last year, regulators advised that the mandate granted at the AGM was not sufficient to proceed with a renounceable rights issue of the shares.
To ensure that the company secures the required funding for its operations in the event that the renounceable rights issue is not fully subscribed, it proposed a post-rights issue private placement, and received shareholders’ approval during an Extraordinary General Meeting (EGM) in Accra on Friday, February 13, 2026.
The funds, when acquired, will also service the Company’s debts, while expanding and addressing funding gaps to position the Company for growth and development.
At the EGM, the Board also received approval to convert loans from CCM Healthcare Investment FZCO in the amount of GH¢4.8 million and from AI Acquisition, in the amount of GH¢239,594.15 into equity.
Chairman of the Board of Intravenous Infusions PLC, Dr lsaac Osei, said, these strategic measures, will provide the company with the necessary capital to strengthen working capital, support expansion plans, improve liquidity, and enhance long-term shareholder value.
Dr Osei said, management would implement a short to medium term strategic policies aimed principally at maximizing revenues and profits.
These policies include continued expansion in both domestic and export markets, product expansion through collaborative partnerships with other foreign and local companies and expansion into new product lines to optimize the production value chain.
It is also to expand the retail parts of the pharmaceutical value chain and enhance the brand name and image through collaboration with key stakeholders and increasing social responsibility work.
“All of these will enable our company to address supply chain challenges to ensure timely availability of raw materials for production,” he added.
Mr Moukhtar Soalihu, Managing Director of Intravenous Infusions PLC, said there were challenges in the past year with respect to financing and “we need to look for funds to be able to fix that.”
He said it had affected the company’s capacity to bring raw materials, which ultimately affected revenues.
The Managing Director said the Company had drawn up a five-year strategic plan, seeking to diversify its product base, “from the current infusions that we are doing, to doing more of injectable.”
Mr Soalihu said, “We are working hard to see how we consolidate the existing gains that we have made, and also to see how we can expand precisely to the export market.”
He said the company was targeting Ivory Coast, Benin, Togo and Burkina Faso and also Liberia and Sierra Leone in its expansion plans.
Post Views: 1
Discover more from The Business & Financial Times
Subscribe to get the latest posts sent to your email.
